Journal article
Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
Heliyon, Vol.10(13), e33871
15/07/2024
Metrics
1 File views/ downloads
34 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Abstract
Purpose
Zoledronic acid can inhibit the activity of osteoclasts, and thus, may slow or inhibit bone loss. The purpose of this study was to systematically evaluate the efficacy and safety of zoledronic acid in the treatment of osteoporosis.
Methods
Four databases, PubMed, Embase, Cochrane Library, and Web of Science, were systematically searched up to December 26, 2022. The primary outcomes included bone mineral density (BMD), carboxy-terminal cross-linked telopeptide of type 1 collagen (CTX), bone-specific alkaline phosphatase (BSAP), procollagen type 1 N-terminal prope-ptide (P1NP), adverse events, and fracture. Secondary outcomes included serum sclerostin level, Visual Analogue Scale (VAS) score, and Oswestry Disability Index (ODI).
Results
A total of 22 randomized controlled trials were included in this meta-analysis. Meta-analysis results showed that zoledronic acid was effective in increasing BMD of the lumbar spine, femoral neck, trochanter and serum sclerostin level; and reduced CTX, BSAP, P1NP, VAS score, and ODI in patients with osteoporosis. Regarding safety, zoledronic acid could reduce the incidence of fractures but had relatively more adverse events.
Conclusion
Zoledronic acid can significantly improve BMD of the lumbar spine, femoral neck and trochanter, and effectively reduce incidence of fracture in patients with osteoporosis, thereby significantly improving patients' quality of life. However, the incidence of adverse events was higher than that of patients treated with placebo.
Details
- Title
- Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
- Creators
- Jianfeng SunMasoud RahmatiWenqing XieGuang YangBingzhou JiDong Keon YonSeung Won LeeRazak M. GyasiGuillermo F. López SánchezPinar SoysalAi KoyanagiLee SmithJae Il ShinYusheng Li
- Publication Details
- Heliyon, Vol.10(13), e33871
- Publisher
- Elsevier Ltd.
- Grant note
- National Key R & D Program of China: 2023YFC3603404 National Natural Science Foundation of China: 82072506, 82272611, 92268115 Hunan Provincial Science Fund for Distinguished Young Scholars: 2024JJ2089 Hunan Young Talents of Science and Technology: 2021RC3025 Provincial Clinical Medical Technology Innovation Project of Hunan: 2023SK2024 National Natural Science Foundation of Hunan Province: 2023JJ30949 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital: 2021KFJJ02, 2021LNJJ05
This work was supported by the National Key R & D Program of China (2023YFC3603404), National Natural Science Foundation of China (82072506, 82272611, 92268115), Hunan Provincial Science Fund for Distinguished Young Scholars (2024JJ2089), Hunan Young Talents of Science and Technology (2021RC3025), Provincial Clinical Medical Technology Innovation Project of Hunan (2023SK2024), National Natural Science Foundation of Hunan Province (2023JJ30949), National Clinical Research Center for Geriatric Disorders, Xiangya Hospital (2021KFJJ02, 2021LNJJ05) .
- Identifiers
- 991013204177602368
- Copyright
- © 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC license, (http://creativecommons.org/licenses/by-nc/4.0/).
- Academic Unit
- National Centre for Naturopathic Medicine
- Language
- English
- Resource Type
- Journal article